GGHC
EW icon

Gilder Gagnon Howe & Co’s Edwards Lifesciences EW Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-41,236
Closed -$3.41M – 251
2022
Q3 		$3.41M Buy
+41,236
New +$3.97M 0.06% 154
2017
Q1 		– Sell
-59,766
Closed -$1.87M – 284
2016
Q4 		$1.87M Buy
59,766
+40,434
+209% +$1.31M 0.04% 164
2016
Q3 		$777K Buy
+19,332
New +$728K 0.01% 195

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Gilder Gagnon Howe & Co's EW Position: Q4 2022 in Review

Gilder Gagnon Howe & Co sold out of Edwards Lifesciences (EW) in Q4 2022, closing a stake of 41,236 shares — an estimated $3.41M sold.

Gilder Gagnon Howe & Co first reported a position in EW in Q3 2016 and held it in 3 quarters. The position peaked at $3.41M in Q3 2022. 1,228 funds tracked by Wall St. Rank hold EW as of Q4 2022.

  • Gilder Gagnon Howe & Co reported no remaining Edwards Lifesciences position as of Q4 2022 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 41,236 Edwards Lifesciences shares in Q4 2022, an estimated $3.41M.
  • Gilder Gagnon Howe & Co first reported a position in Edwards Lifesciences in Q3 2016 and held it in 3 quarters.
  • Gilder Gagnon Howe & Co's Edwards Lifesciences position peaked at $3.41M in Q3 2022.
  • 1,228 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2022.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2022, filed 14 Feb 2023.